Raymond James Initiates Coverage on AppLovin (APP) Stock with a "Strong Buy" Rating
Money

Raymond James Initiates Coverage on AppLovin (APP) Stock with a "Strong Buy" Rating

authorBy Bola Sokunbi
DateJul 04, 2026
Read Time2 min

Raymond James has initiated coverage on AppLovin (APP) stock, a leading AI and technology company, with a "Strong Buy" rating. The investment bank set a price objective of $640.00, citing AppLovin's foray into the e-commerce advertising sector as a crucial catalyst for substantial long-term expansion. This strategic move is expected to lead to favorable adjustments in earnings forecasts, reflecting the company's promising growth trajectory.

Furthermore, the analyst from Raymond James underscored the continuous development of reinforcement learning and consistent improvements to the Axon model, both of which are poised to drive growth within AppLovin's advertising business. The firm views AppLovin as a pivotal mobile in-app advertising platform in a market segment that has historically been undervalued. Separately, Omar Dessouky, an analyst at Bank of America Securities, reaffirmed a "Buy" rating on AppLovin's stock, maintaining a price target of $705.00. This positive outlook is supported by the company's expanding Axon eCommerce presence and a strong long-term growth forecast. AppLovin is recognized for providing comprehensive AI-driven advertising solutions to businesses.

AppLovin's strategic expansion and technological advancements position it as a key player in the evolving digital advertising landscape. The company's commitment to innovation and its robust business model are expected to generate significant value for investors, underscoring the potential for strong returns in the dynamic AI and technology sectors.

More Articles
Money
Market Caution: Jim Cramer's Warning on Cerebras Systems' Volatile Debut
Renowned financial commentator Jim Cramer expressed strong reservations about Cerebras Systems (CBRS) following its turbulent initial public offering. Despite an initial surge, the stock's subsequent decline after an underwhelming earnings report served as a cautionary tale against investing in 'hot' IPOs. Cramer highlighted the dangers of chasing rapidly appreciating stocks immediately after their market debut, emphasizing that such ventures often lead to significant losses for investors.
By Ramit SethiJul 04, 2026
Money
Jim Cramer's Reassessment of Micron's Growth Trajectory
Jim Cramer, a prominent financial commentator, has recently revised his perspective on Micron Technology, Inc. (NASDAQ:MU), moving away from viewing it as a cyclical stock to recognizing its potential as a secular growth story. This shift is attributed to the persistent memory shortage driven by data center demand, enabling Micron to secure favorable long-term pricing. Cramer acknowledged his past misjudgment, influenced by the historical volatility of the memory and storage sector, and highlighted the company's newfound stability and growth prospects within the evolving technological landscape.
By Dave RamseyJul 04, 2026
Money
Jim Cramer's Endorsement of Cardinal Health's Enduring Value
Renowned financial analyst Jim Cramer recently lauded Cardinal Health (CAH) as a robust investment, praising its solid performance despite broader healthcare market shifts. He emphasized the company's consistent strength and future growth potential, highlighting its significance within his investment portfolio. Cardinal Health specializes in distributing pharmaceuticals and medical supplies, playing a crucial role in the healthcare sector.
By Dave RamseyJul 04, 2026
Money
Jim Cramer's Investment Preference: Blackstone Over Blue Owl Amidst Private Credit Discussions
Renowned financial commentator Jim Cramer has expressed a clear preference for Blackstone Inc. (BX) over Blue Owl, citing the former's robust position in the alternative asset management sector. His recommendation comes as he debunks the widespread "private credit chaos" narrative, emphasizing the resilience of private equity stocks. Cramer highlights Goldman Sachs' low investor redemption rates as a key indicator that the industry is overcoming previous concerns. He advises investors to capitalize on the stability and potential of established firms like Blackstone, while cautioning against the perceived higher risk associated with Blue Owl.
By Ramit SethiJul 04, 2026
Money
Healthcare ETF Comparison: State Street vs. Invesco
This article evaluates two prominent healthcare exchange-traded funds (ETFs): the State Street Health Care Select Sector SPDR ETF (XLV) and the Invesco Pharmaceuticals ETF (PJP). It delves into their differing investment strategies, cost efficiencies, fund sizes, and underlying holdings, providing investors with a comprehensive comparison to help them choose between broad market exposure and a concentrated pharmaceutical focus.
By Scott PapeJul 04, 2026